Select recent studies in aggressive B-cell lymphoma looking at (differential) outcomes of patients with HGBL and DHL/THL
| Study . | N . | Patient population/study . | DHL/THL % . | Treatment . | Outcome . |
|---|---|---|---|---|---|
| Rosenwald et al14 | 2383: (MYC-R in 11%) | DLBCL and HGBL/retrospective analysis of prospective and patient registry studies | 5.8% | R-CHOP | MYC-R was associated with shorted PFS and OS; neg. prognostic impact of MYC-R only with BCL2 and/or BCL6 and an IG partner. |
| Dunleavy et al15 | 53 | MYC-R and aggressive B-cell lymphoma/prospective, single-arm, multicenter trial | Approx 44%* had MYC-R (SH); 56% had DHL/THL | DA-EPOCH-R | 4-year EFS and OS were 71% and 77%. No difference for SH vs DHL/THL. |
| Chamuleau et al29 | 82 | MYC-R DLBCL/prospective, single-arm multicenter trial | Approx 27%* had MYC-R (SH); 73% had DHL/THL | R-CHOP + lenalidomide | 2-year EFS and OS were 63% and 73%. |
| Leppä et al17 | 139 | DLBCL and high-IPI score/high-risk cohort/prospective, single-arm, multicenter trial | 12% had DHL | Dose-dense chemo (MTX/R-CHOEP-14, ARA C | 5-year FFS and OS were 74% and 83%. No significant worse outcome for DHL group. |
| McMillan et al16 | 111 | DLBCL and IPI 3-5; 12% had HGBL/prospective study. | 12% had DHL; FISH performed in approx. 50% | R-CODOX-M/R-IVAC | 2-year PFS and OS were 68% and 76%. No worse outcome for DHL. |
| Laude et al18 | 160 | All patients had HGBL/retrospective study | 81% had DHL; 19% had THL | R-CHOP vs intensive chemotherapy | At 32 months, 2 and 4-year PFS were 40% and 28% for R-CHOP; 57% and 52% for intensive therapy. |
| Study . | N . | Patient population/study . | DHL/THL % . | Treatment . | Outcome . |
|---|---|---|---|---|---|
| Rosenwald et al14 | 2383: (MYC-R in 11%) | DLBCL and HGBL/retrospective analysis of prospective and patient registry studies | 5.8% | R-CHOP | MYC-R was associated with shorted PFS and OS; neg. prognostic impact of MYC-R only with BCL2 and/or BCL6 and an IG partner. |
| Dunleavy et al15 | 53 | MYC-R and aggressive B-cell lymphoma/prospective, single-arm, multicenter trial | Approx 44%* had MYC-R (SH); 56% had DHL/THL | DA-EPOCH-R | 4-year EFS and OS were 71% and 77%. No difference for SH vs DHL/THL. |
| Chamuleau et al29 | 82 | MYC-R DLBCL/prospective, single-arm multicenter trial | Approx 27%* had MYC-R (SH); 73% had DHL/THL | R-CHOP + lenalidomide | 2-year EFS and OS were 63% and 73%. |
| Leppä et al17 | 139 | DLBCL and high-IPI score/high-risk cohort/prospective, single-arm, multicenter trial | 12% had DHL | Dose-dense chemo (MTX/R-CHOEP-14, ARA C | 5-year FFS and OS were 74% and 83%. No significant worse outcome for DHL group. |
| McMillan et al16 | 111 | DLBCL and IPI 3-5; 12% had HGBL/prospective study. | 12% had DHL; FISH performed in approx. 50% | R-CODOX-M/R-IVAC | 2-year PFS and OS were 68% and 76%. No worse outcome for DHL. |
| Laude et al18 | 160 | All patients had HGBL/retrospective study | 81% had DHL; 19% had THL | R-CHOP vs intensive chemotherapy | At 32 months, 2 and 4-year PFS were 40% and 28% for R-CHOP; 57% and 52% for intensive therapy. |
Of cases tested.
ARA C, cytarabine; CHOEP, CHOP with etoposide; FFS, failure-free survival; MTX, methotrexate.